Identification of Common Molecular Subtypes of Asian Hepatocellular Carcinoma and Cholangiocarcinoma.

Anuradha Budhu  
*National Cancer Institute, Bethesda, United States, budhua@mail.nih.gov*

Jittiporn Chaisaingmongkol  
*Chulabhorn Research Institute, Bangkok, Thailand, jittiporn@cri.or.th*

Hien Dang  
*National Cancer Institute, Bethesda, United States, danghi@mail.nih.gov*

*See next page for additional authors*

Follow this and additional works at: [http://scholarscompass.vcu.edu/hepa_cancers](http://scholarscompass.vcu.edu/hepa_cancers)

*Part of the [Medicine and Health Sciences Commons](http://scholarscompass.vcu.edu/hepa_cancers)*

© The Author(s)
Authors
Anuradha Budhu, Jittiporn Chaisaingmongkol, Hien Dang, So Mee Kwon, Siritida Rabibhadana, Benjarath Pupacdi, Marshonna Forgues, Yosawat Pomyen, Vajarabhongsa Bhudhisawasdi, Nirush Lertprasertsuke, Anon Chotirosniramit, Chawalit Pairojkul, Chirayu Auewarakul, Thaniya Sricharunrat, Kannika Phornphutku, Suleeporn Sangrajrang, Maggie Cam, Ping He, Stephen M. Hewitt, Xiaolin Wu, Snorri S. Thorgeirsson, Paul S. Meltzer, Christopher Loffredo, Robert H. Wiltrout, Curtis C. Harris, Chulabhorn Mahidol, Mathuros Ruchirawat, and Xin W. Wang

This abstract accepted for presentation is available at VCU Scholars Compass: http://scholarscompass.vcu.edu/hepa_cancers/30
Identification of Common Molecular Subtypes of Asian Hepatocellular Carcinoma and Cholangiocarcinoma.

Anuradha Budhu\(^1\), Jittiporn Chaisingmongkol\(^1,2\), Hien Dang\(^1\), So Mee Kwon\(^1\), Siritida Rabibhadana\(^2\), Benjarath Pupacdi\(^2\), Marshonna Forgues\(^1\), Yotsawat Pomyen\(^1\), Vajarabhongsa Bhudhisawasdi\(^3\), Nirush Lertprasertsuke\(^4\), Anon Chotirosniramit\(^4\), Chawalit Pairojkul\(^3\), Chirayu U. Auewarakul\(^6\), Thaniya Sricharunrat\(^5\), Kannika Phornphutkul\(^6\), Suleeporn Sangrajrang\(^7\), Maggie Cam\(^1\), Ping He\(^8\), Stephen M. Hewitt\(^1\), Xiaolin Wu\(^1\), Snorri S. Thorgeirsson\(^1\), Paul S. Meltzer\(^1\), Christopher A. Loffredo\(^8\), Robert H. Willtrout\(^1\), Curtis C. Harris\(^1\), Chulabhorn Mahidol\(^2\), Mathuros Ruchirawat\(^2\) and Xin Wei Wang\(^1\)

\(^1\)National Cancer Institute, Bethesda, United States; \(^2\)Chulabhorn Research Institute, Bangkok, Thailand; \(^3\)Khon Kaen University, Khon Kaen, Thailand; \(^4\)Chiang Mai University, Chiang Mai, Thailand; \(^5\)Chulabhorn Hospital, Bangkok, Thailand; \(^6\)Rajavej hospital and Lampang Cancer Center, Chiang Mai Thailand; \(^7\)National Cancer Institute, Bangkok, Thailand; and \(^8\)FDA, Bethesda, United States; \(^9\)Georgetown University Medical Center, Washington, DC, United States

Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are clinically disparate primary liver cancers (PLC) with etiological and biological heterogeneity and are the primary cause of cancer mortality in Thailand. The Thailand Initiative in Genomics and Expression Research for Liver Cancer (TIGER-LC) consortium was established to identify genomic factors related to PLC risk, genetic susceptibility, and progression. We determined molecular subtypes among PLC patients by systematic integration of genomic, transcriptomic, and metabolic profiles. Genome wide profiling of 398 surgical specimens derived from 199 PLC patients was performed by Affymetrix HTA2.0 (transcriptome), Affymetrix Genome-Wide Human SNP Array 6.0 (somatic copy number alterations) and Metabolon’s DiscoveryHD4 platform (metabolome). Unsupervised Consensus Clustering (cCluster), Subclass Mapping (SM), Gene Set Enrichment Analysis (GSEA), class comparison, loss of heterozygosity and minimum segmentation, Pearson and rank correlation algorithms were used to analyze and validate omics data in 852 Asian and Caucasian PLC cases. Thai HCC and ICC consisted of several stable molecular subtypes linked to similar prognosis that were validated in 247 Chinese HCC, 156 Asian American HCC and 182 Japanese ICC, but not in 163 European American HCC or 104 Caucasian ICC patients. While ICC and HCC share recurrently mutated genes, including TP53, ARID1A, and ARID2, mitotic checkpoint anomalies distinguish the C1 subtype with key drivers PLK1 and ECT2, whereas the C2 subtype is linked to obesity, T-cell infiltration and bile acid metabolism. Thus, Asian ICC and HCC, while clinically treated as separate entities, share common molecular subtypes with similar actionable drivers to improve precision therapy.